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Cytomegalovirus (CMV) is a common congenital infection and an important cause of 25 sensorineural hearing loss (SNHL) [1, 2] . A minority of those infected will have clinically 26 detectable disease at birth, but 13% of those without disease will subsequently develop 27 significant impairments, particularly SNHL [3] . 28 Antiviral treatment improves hearing and neurodevelopmental outcomes when started in 29 the first month of life in symptomatic newborns [4, 5] . There are no randomized studies to 30 support treatment of babies without detectable disease at birth and the search for 31 prognostic markers for adverse long term outcome in these newborns is ongoing . 32
Natural history studies in adult transplant recipients show that high viral load and viral 33 kinetics in whole blood correlate with the development of CMV end-organ disease [6] with 34 viruria independently associated with disease in renal transplant patients. 35
High viral load has also been associated with poor long-term outcomes in congenitally 36 infected babies in some studies [7] [8] [9] [10] [11] but not others [12] . A major limitation is the lack of 37 adequate numbers of babies without disease at birth that subsequently develop CMV-38 related morbidity. As SNHL is progressive, the duration of follow-up required to produce 39 meaningful results further impacts on the conduct of such studies [13] . 40 Data in infants largely reports single measurements of viral load rather than sequential 41 monitoring coupled with viral kinetic modelling. A recent study in neonates treated for 42 congenital CMV (CCMV) observed a correlation between higher burden of CMV DNA in the 43 blood in the first 6 weeks of treatment and subsequent SNHL [5] . Given the known 44 6 prolonged urinary excretion of CMV in those infected in early life it is possible that virus 45 kinetics differ between body fluids in this group, but no data exist currently. 46
Further defining the natural history of CMV virus kinetics in different body fluids in those 47 with CCMV could aid our understanding of the pathogenesis of this virus and assist in 48 developing biomarkers. 49
OBJECTIVES 50
This study aimed to define the kinetics of CMV replication in blood, urine and saliva in a 51 group of babies receiving treatment. 52
STUDY DESIGN 53
The Viral load and Immunology in Congenital CMV (VICC) study recruited babies into an 54 ethically approved protocol in the UK. 19 babies with CCMV were recruited from 7 study 55 sites between 2008 and 2011. After CCMV diagnosis, participants in the study provided 56 blood, urine and salivary samples at set time-points during and after treatment and up to 57 two years of age. CMV quantitative analysis was performed in the Department of Virology 58 at the Royal Free Hospital. Only the 11 babies that received treatment, with sufficient viral 59 load results for meaningful analysis, are presented here (see supplemental data). 60
An ethically approved treatment registry for CCMV was also active in the UK during the 61 same time period. Babies in this registry with multiple entries for CMV viral load were 62 included for analysis (N=2)(see supplemental data). The parent(s) or legal guardian(s) of 63 participants in both the above studies provided written informed consent. 64
Multiple samples were also received at our laboratory from 3 treated babies as part of 65 routine clinical care. 66
Definitions: 67
CCMV was confirmed if a sample tested positive for CMV within 21 days of life. 68
Symptomatic infection was defined according to criteria used in a previously published 69 randomised controlled trial (RCT) of treatment [4] . 70
Salivary swab acquisition: 71
Salivary samples were taken using neonatal flocked swabs (Sterilin™ Cambridge, UK) at least 72 one hour after the baby's last feed. Swabs were resuspended in 1ml virus transport 73 medium (VTM) prior to extraction. 74
Detection and quantitation of CMV DNA: 75
Total nucleic acid was extracted using the commercial Nuclisense Easymag system 76 (Biomerieux, Basingstoke UK) according to manufacturer's instructions. CMV viral load was 77 then determined using an in-house real-time quantitative PCR as described previously 78 (lower limit of detection being 200 copies/ml, (168 IU/ml)). [14] . 79
An estimate of the volume of saliva held on swabs was obtained by weighing swabs pre-and 80 post-saturation in saliva. The mean of 3 samples gave an estimated volume of 27ul of 81 saliva which allowed for calculations of CMV viral load/ml of saliva. 82
83
Measurement of ganciclovir levels: 84 8 Ganciclovir (GCV) levels were determined by the Bristol Antimicrobial reference laboratory 85 as described in detail elsewhere [15] . Virus decline was calculated using methodology described previously [16] . The slope of 98 decline of log e (ln) viral load was computed using segmental regression in GraphPad Prism 99 (GraphPad Software, La Jolla, CA) with X0 constraint for decline set at the point where the 100 phase of most rapid viral decline appeared to end. Virus half-life was then defined using the 101
For the calculation of the basic reproductive number (Ro) after cessation of therapy the 103 following formula was used: 104 Ro = 1+ r/ e rt where r is the growth rate of virus after stopping therapy, Is the death rate 105 of a CMV infected cell (taken from Emery et al, 1999) and t is a time delay between infection 106 and production of new virions (set at 2 days) [16] . 107
RESULTS 108

Participants: 109
The study included viral load data from 17 babies treated for congenital CMV. All babies 110 had clinical signs or symptoms of congenital infection with central nervous system (CNS) 111 involvement. SNHL was the only evidence of suspected CNS disease in one neonate. 112
Treatment was with intravenous ganciclovir (iv GCV) at a dose of 5-6mg/kg twice daily (bid) 113 (n=10), oral valganciclovir (VGCV) at a dose of 10-17mg/kg bid alone (n=2) or a combination 114 of iv GCV followed by VGCV (n=5). All babies receiving mixed treatment commenced with iv 115 GCV for a minimum of 6 days. 116
Baseline viral loads: 117
In blood and urine samples 13/17 and 14/15 were taken prior to, or on the day of, 118 treatment initiation. In saliva 6/8 baseline specimens were acquired after day 0 of 119 treatment (median 3 days). 120
DNAemia was detected in 15/17 (88%) neonates at baseline. All urine and saliva samples 121 were CMV DNA positive. Both the neonates with undetectable DNAemia had samples taken 122 prior to treatment commencing. Median and interquartile ranges (IQR) of CMV loads at 123 baseline in blood, urine and saliva were 3.8 (3.3-4.2), 7.7 (7.0-8.4) and 7.2 (6.8-8.3) log 10 124 genomes/ml with corresponding means of 3.8 (SD ± 0.8), 7.7 (± 0.9) and 7.3 (± 1.5) ( Figures  125   1 and 2) . 126
More than one blood sample and more than one urine sample were taken in five neonates 127 before treatment. In 2/5 of these babies viral load in blood and urine decreased by more 128 than 1.0 log 10 genomes/ml (blood: range 0.2-1.5 log 10 genomes/ml over 6-21 days; urine: 129 range 0.1-1.6 log 10 genomes/ml over a period of 1-23 days). 130
End of treatment viral load: 131
At the end of a 42 day treatment course CMV remained detectable in 9/14 blood samples 132 (65%), 9/12 urine samples (75%) and 4/7 salivary swabs (57%). Median CMV load in blood, 133 urine and saliva in babies with virus still detectable was 2.8 log 10 genomes/ml (IQR 2.5-3.5), 134 2.9 log 10 genomes/ml (IQR 2.7-3.9) and 4.0 log 10 genomes/ml (IQR 3.2-5.5) respectively. 135 CMV loads were significantly lower at the end of treatment in blood and urine, but not 136 saliva, compared to baseline values (P = <0.01, 0.02 and 0.13 respectively). 137
CMV kinetics during therapy: 138
Baseline CMV loads were approximately 4.0 log 10 genomes/ml higher at the start of 139 treatment in urine and saliva as compared with blood but this difference narrowed during 140 the 42 days of treatment ( Figure 1 ). In keeping with this observation, viral decline between 141 the start and end of 42 days treatment was higher in urine and saliva compared to blood 142 with an absolute decline of -1.2 log 10 genomes/ml (IQR -1.8 to -0.9) observed in 14 paired 143 blood samples compared to -4.4 log 10 genomes/ml (IQR -5.5 to -3.8) in urine (N=10) and -4.8 144 log 10 genomes/ml (IQR -5.2 to -3.9) in saliva (N=7)( Table 1) . In 2/14 paired blood samples no 145 decline was observed during treatment whereas CMV DNA decreased in all urine and 146 salivary samples. 147 CMV DNA decline in blood and urine was more rapid during the first 7 days of treatment 148 when compared to the full 42 days of treatment ( Table 1) . Salivary samples from early 149 sampling points were too few to allow for analysis. 150
Using these data, the half-life of decline (T 1/2 ) was calculated using segmental regression of 151 the most rapid phase of virus decline (examples shown in Figure 3 ). The median T 1/2 in 152 blood of 14 neonates was 2.4 days (IQR 1.9-3.3 days), in urine it was 2.0 days (IQR 1.3-2.6) 153 (N=14) and in saliva 1.5 days (IQR 1.4-2.4) (N=4). 154
Post therapy kinetics: 155
Once treatment had stopped, a rebound of CMV DNA levels was observed within 1 week in 156 4/8 blood, 6/9 urine and 1/5 saliva samples. The median increase in CMV load over the first 157 7 days post-treatment was 0.52 (blood), 1.04 (urine) and 2.05 (saliva) log 10 genomes/ml 158 ( Figure 2) . Where no rebound was observed virus had been undetectable at the end of 159 treatment in 2/4 (blood), 1/3 (urine) and 2/4 (saliva) babies; in the remaining babies virus 160 was still detectable but continued to decrease after treatment discontinuation. 161
Maximum virus levels following treatment were at age 3 months in blood and age 6 months 162 in urine and saliva samples (Figure 2 ). Median maximum virus load was not significantly 163 different from baseline in blood (3.78 vs 2.96 log 10 genomes/ml respectively; P=0.3) or saliva 164 (7.39 vs 7.16 log 10 genomes/ml respectively; P = 0.72). Urine CMV load was, however, 165 significantly lower at 6 months of age compared to baseline (median 5.94 vs 7.74 log 10 166 genomes/ml respectively; P= <0.01). 167
12
The basic reproductive number (Ro) was calculated using the growth rate derived from the 168 post therapy virus rebound and previous estimates of the death rate of a CMV infected cell 169 in vivo (~0.98 day). This calculation revealed a median Ro value of CMV in blood of 2.3 (n=2) 170 in urine of 2.8 (n=2) and in saliva of 4.6 (n=1). 171
Long-term viral control: 172
CMV DNA remained detectable in no blood samples (n=6) at month 12 but in most urine 173 (7/7) and saliva (6/8) samples. By 24 months CMV DNA remained undetectable in all blood 174 samples (n=3) but was detectable in 2/3 urine and 1/3 saliva samples. In urine the median 175 CMV load at 12 months was 4.7 log 10 genomes/ml (IQR 4.5-5.8)(N=7) which was significantly 176 lower than the baseline load (7.7 log 10 genomes/ml (p<0.01)). Similarly, salivary viral load 177 was significantly lower at month 12 than at baseline [4.5 log 10 (IQR 2.5-5.1) vs 7.56 log 10 178 (IQR 6.76-8.44) genomes/ml respectively (p <0.01)]. 179
Ganciclovir levels: 180
Ganciclovir levels were mostly below quoted reference values of 0.5 mg/L (trough) and 181 7.0mg/L (peak) (Figure 4) . Plotting log 10 virus decline during the first 7 days of treatment 182 against peak and trough GCV levels at day 7 did not reveal any significant association 183 between these two parameters in the 5 babies studied (supplemental data). 184
The results of this study provide insight into the kinetics of CMV in different biological 186 compartments in neonates during and after antiviral therapy. Despite the differences in 187 baseline CMV load, half-lives during the initial phase of treatment were comparable across 188 compartments (P = 0.1-0.4 for inter-group comparisons) and similar to the 2 days observed 189 in infrequently sampled adult immunocompromised hosts [16] . 190
In contrast to data from studies in adult transplant patients with similar starting virus loads 191 over half of the neonates still had DNAemia detectable at the end of the 6 week treatment 192 course [14] . This observation and that of an initially rapid virus decline followed by a nadir 193 is in keeping with similar observations in treated neonates [17] . 194
The reasons for this incomplete suppression in neonates are unclear. In the setting of CMV 195 replication in HIV infection the efficacy of iv GCV (5mg/kg/bid) has been estimated at 91.5% 196 [18] but where plasma levels are lower the efficacy will be reduced. Therapeutic drug 197 monitoring of GCV levels in the neonates enrolled in this study indicate that plasma GCV 198 levels were low but consistent with other data in children [15] . Higher levels of GCV may be 199 needed in this population to fully inhibit replication. Analysis of the CMV UL97 locus 200 showed no evidence of mutations known to confer GCV resistance. 201
Alternatively, persistent viremia may represent continued virus excretion from 'sanctuary 202 sites' inaccessible to antiviral agents. Given the increased audiological and neurological 203 morbidity observed in CCMV when compared to immunocompromised adults, the inner ear 204 or CNS would be possible sources of such virus reservoirs and drug penetration at these 205 sites correspondingly suboptimal [19] . Testing such a hypothesis is challenging since no 206 data evaluating virus persistence in CSF exist, nor is this likely to be ethically acceptable. 207
Although rebound of virus was common in all body fluids in the first week post-treatment, 208 maximal rebound occurred earlier in blood when compared to urine and saliva; the rebound 209 in DNA-emia is consistent with other recent reports during neonatal treatment [5] . Only 210 14 virus in urine rebounded to a level significantly lower than baseline in our study. This is an 211 important observation if the 'threshold' concept of CMV disease proposed in adults applies 212 to CCMV [20] . 213
If virus is not in a steady state at the initiation of therapy then the dynamic models adopted 214 may not be fully applicable. However, congenital infection often occurs months before birth 215
and the values obtained here are consistent with those derived in adults. The growth of 216 CMV during the rebound phase allowed us to estimate Ro for CMV during this resurgence in 217 replication. The Ro values are relatively modest at 2.3 and 2.8 for blood and urine 218 respectively, consistent with those observed in D+R-solid organ transplant recipients [21] . 219
Overall the data presented here imply that initial viral response to treatment is similar to 220 that observed in adult immunocompromised hosts. However, following this initial response, 221 CMV replication patterns differ in neonates when compared to immunocompromised 222 adults. In keeping with this altered virus kinetics is the ongoing audiological damage and 223 neurological damage unique to this age group. The reasons for this remain to be elucidated Sisnett (Oxford University Hospital's NHS Trust). We would like to thank the parents who gave consent for their children to be involved with studies and the CMV parent group who reviewed study concepts and critically appraised the parent information sheets for the two ethically approved studies (cmvaction.org).
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